Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q96HI0

UPID:
SENP5_HUMAN

ALTERNATIVE NAMES:
Sentrin/SUMO-specific protease SENP5

ALTERNATIVE UPACC:
Q96HI0; B4DY82; Q96SA5

BACKGROUND:
The enzyme Sentrin-specific protease 5, also known as Sentrin/SUMO-specific protease SENP5, is integral to the SUMOylation pathway. It catalyzes the maturation of SUMO3 and the removal of SUMO2 and SUMO3 from proteins, with limited activity against SUMO1. Its requirement for cell division underscores its importance in maintaining cellular integrity and function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Sentrin-specific protease 5 offers a promising avenue for the development of novel therapeutic approaches. Given its crucial role in the SUMO pathway and cell division, targeting this protease could lead to innovative treatments for diseases where regulation of SUMOylation and cell division is beneficial.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.